Department of Critical Care Medicine, the Affiliated Hospital of Putian University, No. 999 Dongzhen East Road, Licheng District, Putian, 351100, Fujian, China.
School of Ophthalmology&Optometry, Wenzhou Medical University, Wenzhou, 325000, China.
Naunyn Schmiedebergs Arch Pharmacol. 2024 Jul;397(7):4713-4725. doi: 10.1007/s00210-023-02897-5. Epub 2023 Dec 22.
Septic cardiomyopathy (SCM) is manifested by impairment of cardiac contractile function with myocardial mitochondrial dysregulation. Natural product, songorine (SGR), a diterpenoid alkaloid derived from the lateral root of Aconitum carmichaeli, has been reported for the treatment of heart failure. Here, the protective role of SGR in heart injury of SCM was investigated and its underlying action of mechanism was explored. Firstly, the mouse and cardiomyocytes (H9C2 cell) SCM model induced by LPS were established to evaluate the therapeutic effect of SGR. The in vivo results exhibited that SGR rescued the survival rate of SCM mice, restored the loss of ejection fraction (EF) and fractional shortening (FS), and reduced left ventricular systolic diameter and left ventricular diastole diameter (LVIDs, LVIDd) by echocardiography. SGR improved the mitochondrial biosynthesis and myocardial fiber structure and arranged them neatly by transmission electron microscope (TEM). Further, SGR inhibited inflammatory targets myeloperoxidase (MPO) and tumor necrosis factor (TNF-α), interleukin-1β (IL-1β), interleukin-6 (IL-6), and plasminogen activator inhibitor-1 (PAI-1). And SGR activated the mitochondrial biosynthesis-related peroxisome proliferator-activated receptor-γ coactivator-1α (PGC-1α), β-catenin, and matrix metallopeptidase 2 (MMP2) proteins. Meanwhile, the in vitro results showed that SGR promoted the increased the myocardial H9C2 cell viability, and mitochondrial biosynthesis and structure. SGR also blocked the inflammatory factors and reversed PGC-1α, β-catenin, and MMP2 in vitro, while SGR alleviated the myocardial cell apoptosis via flow cytometry. The findings indicate that SGR mitigates sepsis-caused myocardial damage by Wnt/β-catenin signaling pathway-mediated mitochondrial biosynthesis. SGR may be a promising candidate for treatment of SCM.
脓毒症性心肌病(SCM)表现为心肌收缩功能障碍,心肌线粒体失调。天然产物,歌柔碱(SGR),一种来源于乌头碱侧根的二萜生物碱,已被报道用于治疗心力衰竭。在此,研究了 SGR 在 SCM 心肌损伤中的保护作用及其潜在的作用机制。首先,建立了 LPS 诱导的小鼠和心肌细胞(H9C2 细胞)SCM 模型,以评估 SGR 的治疗效果。体内结果表明,SGR 挽救了 SCM 小鼠的存活率,恢复了射血分数(EF)和缩短分数(FS)的丧失,并通过超声心动图降低了左心室收缩直径和左心室舒张直径(LVIDs,LVIDd)。SGR 通过透射电镜(TEM)改善了线粒体生物合成和心肌纤维结构,并将其排列整齐。此外,SGR 抑制了炎症靶点髓过氧化物酶(MPO)和肿瘤坏死因子(TNF-α)、白细胞介素-1β(IL-1β)、白细胞介素-6(IL-6)和纤溶酶原激活物抑制剂-1(PAI-1)。并且 SGR 激活了线粒体生物合成相关过氧化物酶体增殖物激活受体-γ共激活物-1α(PGC-1α)、β-连环蛋白和基质金属蛋白酶 2(MMP2)蛋白。同时,体外结果表明 SGR 促进了心肌 H9C2 细胞活力、线粒体生物合成和结构的增加。SGR 还在体外阻断了炎症因子,并逆转了 PGC-1α、β-连环蛋白和 MMP2,同时通过流式细胞术减轻了心肌细胞凋亡。这些发现表明,SGR 通过 Wnt/β-连环蛋白信号通路介导的线粒体生物合成减轻了脓毒症引起的心肌损伤。SGR 可能是治疗 SCM 的有前途的候选药物。